Men with PSA levels below 10ng/mL at time of surgical treatment for benign prostatic hyperplasia are at low risk of aggressive cancer, a large population-based study shows.

Danish researchers say their results should reassure clinicians that, in the absence of any red flags, patients who fall into this category do not need to be monitored differently than other men.

Their conclusion is based on the finding of a 15-year cumulative incidence of cancer-specific death post-benign transurethral resection of the prostate (TURP) of 1.4% for all men and 0.8% for those with PSA below 10ng/mL.

“Prostate tumours that are hard to find are highly unlikely to lead to mortality,” doctors from the Copenhagen University Hospital reported in Cancer.